Imprint
Content
Dr. Erkens Consulting Group
Industriestraße 13
D- 64380 Roßdorf
Germany
Tel: +49 6154 – 69 67 944 • Mobil +49 179 – 2 41 10 29
Message to Dr. Erkens Consulting Group
tax no. 73 841 210 966
Webmaster
be-sign.net • Bernd Scheurer
Mainstr. 2, 64390 Erzhausen
Tel.: +49 151 – 50 411 034
Message to Webmaster
Web: www.be-sign.net
Scripting
Stefan Klose
(M.Sc. Informatik)
Copyrights
Unless otherwise stated, the copyright of the photos used lies with Dr. Erkens Consulting Group.
The corresponding statutory provisions apply to all registered brands, trade names and logos used on our website, even if they are not marked as such in the respective places.
- Photo Home: ABWI74/pixabay
- Photo Business area Strategie | Consulting: Headway/unsplash
- Photo Business area Management | Leadership: Marten van den Heuvel/unsplash
- Photo Business area Analyses | Market research: Carlos Muza/unsplash
- Photo Business area Marketing | Sales: Diggity Marketing/unsplash
- Photo Business area Communication | Education: Marko Pekić/unsplash
- Photo News: Andrys/pixabay
- Photo Company: Dagobert1980/pixabay
- Photo: Meeting: jmexclusives/pixabay
- Photo: Microscope: kkolosov/pixabay
- Photo Services: paulbr74/pixabay
- Photo Network: StockSnap/pixabay
- Photo Academy: plugrafico/pixabay
- Photo Blog: Free-Photos/pixabay
- Photo: Career: rolandmey/pixabay
- Photo Contact: Skitterphoto/pixabay
- Photo MediaCenter: JESHOOTS-com/pixabay
- Photo GTC, Imprint, Privacy: Cleverpix/pixabay
Adress
Dr. Erkens Consulting Group
Industriestraße 13
64380 Roßdorf
Tel: +49 (0)6154 – 6967 – 944
Mobil +49 (0)179 – 2 41 10 29
info@dr-erkens-consulting.de
Social
News
Dr. Erkens Consulting Group
- Website-Relaunch of Dr. Erkens Consulting Group
Source: Dr. Erkens Consulting Group 09/2020 - Integrated Pharma-News at Dr. Erkens Consulting Group Website
Source: Dr. Erkens Consulting Group 09/2020
Pharma Letter
- Organon and Samsung look for edge in battle of the biosimilars
- Russian drugmaker R-Pharm eyes buying Takeda plant in Yaroslavl
- FibroGen stock slumps 22% as DMD candidate fails in Phase III
- Kyowa Kirin picks up Japanese approval for Orkedia
- Injectable Tecentriq wins first approval from British regulator
Pharma Relations
Pharma Times
PZ online
- Spikevax XBB.1.5: Angepasster Moderna-Impfstoff ab 1. Oktober bestellbar
- Pharmazeutische Dienstleistungen: So klappt die Medikationsanalyse im Heim
- Neue Applikationsform: Saugnapf statt Spritze
- DAT-Leitantrag: Einstimmige Forderung nach Honorarerhöhung
- Gendermedizin: Diese Arzneistoffe wirken bei Frauen anders
Our Place on Earth
Kartenbild: OpenStreetMap, ODbL 1.0